LIVIVO - Search results -

Search results

Result 1 - 10 of total 29

Search options

Article ; Online: Vaccinatie van immuungecompromitteerde patiënten.

Goorhuis, Abraham / Garcia-Garrido, Hannah M / Vollaard, Albert M

2020 Volume 164

Abstract: Immunocompromised individuals are at increased risk of infectious diseases and their complications. The main examples of these are pneumococcal disease and influenza, infections that are both vaccine-preventable. However, responses to vaccination are ... ...

Title translation	Vaccination of immunocompromised patients: when and when not to vaccinate.
Abstract	Immunocompromised individuals are at increased risk of infectious diseases and their complications. The main examples of these are pneumococcal disease and influenza, infections that are both vaccine-preventable. However, responses to vaccination are often impaired in immunocompromised patients. In addition, live-attenuated vaccines, including the measles-mumps-rubella and yellow fever vaccine, cannot be administered to these patients for safety reasons. In view of the decreasing herd immunity caused by a drop in global vaccination coverage, immunocompromised individuals are at increased risk of infections such as measles, especially during travel abroad. Despite these developments, the improved quality of life resulting from novel treatment options means that immunocompromised patients are travelling more and further than ever. It is the responsibility of the treating physician of the immunocompromised individual to ensure that all the required vaccines are provided in time. To this end, the physician may also refer the patient to the general practitioner or travel clinic for the actual vaccination.
MeSH term(s)	Female ; Humans ; Immunocompromised Host ; Measles-Mumps-Rubella Vaccine/adverse effects ; Middle Aged ; Travel ; Vaccines, Attenuated/adverse effects ; Yellow Fever Vaccine/adverse effects ; Young Adult
Chemical Substances	Measles-Mumps-Rubella Vaccine ; Vaccines, Attenuated ; Yellow Fever Vaccine
Language	Dutch
Publishing date	2020-09-03
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Influenzavaccinatie bij hartpatiënten voorkomt cardiale complicaties.

Vollaard, Albert M / Slok, Edwin N E / van Dijkman, Paul R M / Dekkers, Olaf M / Groeneveld, Geert H

Nederlands tijdschrift voor geneeskunde

2023 Volume 167

Abstract: Influenza infection increases the risk of cardiovascular complications and mortality in patients with heart disease. In patients with coronary artery disease influenza vaccination has been shown to reduce cardiovascular mortality, but high-quality ... ...

Title translation	Influenza vaccination as secondary prevention for cardiovascular disease.
Abstract	Influenza infection increases the risk of cardiovascular complications and mortality in patients with heart disease. In patients with coronary artery disease influenza vaccination has been shown to reduce cardiovascular mortality, but high-quality evidence was missing. New trial data from a RCT in patients shortly after myocardial infarction has confirmed the significant reduction of the risk of major adverse cardiovascular events (MACE) and cardiovascular death after influenza vaccination. Also in patients with heart failure the first published RCT in heart failure shows a clinical benefit of influenza vaccination versus placebo during the influenza season, confirming preceding observational studies. Meta-analyses from the study data estimate that after influenza vaccination a risk reduction of MACE of at least 25% is possible in patients with heart disease. The current underutilization of influenza vaccines in heart patients should be addressed because influenza vaccination has proven to be an effective and safe instrument for secondary prevention.
MeSH term(s)	Humans ; Influenza, Human/complications ; Influenza, Human/prevention & control ; Cardiovascular Diseases/drug therapy ; Secondary Prevention ; Influenza Vaccines ; Myocardial Infarction/complications ; Heart Failure/complications ; Vaccination
Chemical Substances	Influenza Vaccines
Language	Dutch
Publishing date	2023-10-12
Publishing country	Netherlands
Document type	English Abstract ; Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors.

Groeneveld, Geert H / Wijn, Dirk H / Vollaard, Albert M

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2019 Volume 70, Issue 7, Page(s) 1519

MeSH term(s)	Humans ; Immune Checkpoint Inhibitors ; Influenza Vaccines/adverse effects ; Influenza, Human/drug therapy ; Influenza, Human/prevention & control ; Neoplasms/drug therapy ; Vaccination ; Vaccines, Inactivated/therapeutic use
Chemical Substances	Immune Checkpoint Inhibitors ; Influenza Vaccines ; Vaccines, Inactivated
Language	English
Publishing date	2019-06-17
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciz512
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide in people living with HIV on combination antiretroviral therapy

Garrido, Hannah M. Garcia / Schnyder, Jenny L. / Haydari, Beheshta / Vollaard, Albert M. / Tanck, Michael W.T / de Bree, Godelieve J. / Meek, Bob / Grobusch, Martin P. / Goorhuis, Abraham

International journal of antimicrobial agents. 2022 June 19,

2022

Abstract: People living with HIV (PLWH) are at increased risk of pneumococcal infections compared with the general population. The objective of this study was to investigate the immunogenicity of the combined pneumococcal vaccination schedule in PLWH. : In this ... ...

Abstract	: People living with HIV (PLWH) are at increased risk of pneumococcal infections compared with the general population. The objective of this study was to investigate the immunogenicity of the combined pneumococcal vaccination schedule in PLWH. : In this prospective cohort study, adult PLWH on antiretroviral therapy and HIV negative controls received the 13-valent pneumococcal conjugate vaccine (PCV13) at baseline followed by the 23-valent polysaccharide vaccine (PPSV23) at month 2. Serotype-specific IgG levels of 24 vaccine serotypes were measured (months 0, 2, 4, 6, 12). The primary outcome was seroprotection at month 4, defined as the proportion of patients with a post-immunization IgG concentration of ≥1.3 µg/mL for ≥70% (17/24) of vaccine serotypes. : Samples of 120 patients were analysed. Seroprotection at month 4 was 49% (39/80) for PLWH and 82% (28/34) in controls. At month 12, seroprotection had decreased to 23% (18/79) and 63% (22/35), respectively. Nadir CD4 counts ≥ 200 cells/mm³, preserved kidney function and co-administration of the diphtheria-tetanus-polio (DTP) vaccine were associated with better seroprotection among PLWH. IgG levels of both PLWH and controls (all 24 vaccine serotypes) were significantly higher compared with baseline at all timepoints. : Although IgG levels of all 24 vaccine serotypes increased significantly in both PLWH and controls, only a minority of PLWH achieved seroprotection after PCV13 followed by PPSV23. In addition, protective immunity waned rapidly. Further research into alternative vaccinations strategies for PLWH is needed, such as vaccination schedules with higher-valent pneumococcal vaccines. The DTP vaccine may augment pneumococcal vaccination responses.
Keywords	Streptococcus pneumoniae ; adults ; antiretroviral agents ; cohort studies ; immunogenicity ; people ; polysaccharides ; renal function ; risk ; serotypes ; vaccination ; vaccines
Language	English
Dates of publication	2022-0619
Publishing place	Elsevier Ltd
Document type	Article
Note	Pre-press version
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2022.106629
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾

Article: Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy.

Garcia Garrido, Hannah M / Vollaard, Albert / D'Haens, Geert R / Spuls, Phyllis I / Bemelman, Frederike J / Tanck, Michael W / de Bree, Godelieve J / Meek, Bob / Grobusch, Martin P / Goorhuis, Abraham

Vaccines

2022 Volume 10, Issue 5

Abstract: Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), ... ...

Abstract	Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23), in adults with and without immunosuppressive therapy. We performed a prospective cohort study among adults using conventional immunomodulators (cIM), biological immunomodulators (bIM), combination therapy, and controls during 12 months. The primary outcome was seroprotection, defined as the proportion of patients with a postimmunization IgG concentration of ≥1.3 µg/mL for at least 70% (17/24) of the serotypes of PCV13 + PPSV23. We included 214 participants. For all 24 vaccine serotypes, IgG levels increased significantly in both treatment subgroups and controls, with peak seroprotection rates of 44% (combination therapy), 58% (cIM), 57% (bIM), and 82% (controls). By month 12, seroprotection had decreased to 24%, 48%, 39%, and 63%, respectively. Although pneumococcal vaccination with PCV13 + PPSV23 was immunogenic in all treatment groups, impaired vaccination responses were observed in patients using immunosuppressive medication. Apart from the obvious recommendation to administer vaccines before such medication is started, alternative vaccination strategies, such as additional PCV13 doses or higher-valent pneumococcal vaccines, should be investigated.
Language	English
Publishing date	2022-05-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10050795
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Uitbraak van monkeypox: een nieuwe pandemie?

de Stoppelaar, Sacha F / Hoornenborg, Elske / van Rijckevorsel, Gini / Vollaard, Albert / Brandwagt, Diederik A H / de Vries, Henry J C / Schinkel, Janke / Welkers, Matthijs R A / Goorhuis, A

Nederlands tijdschrift voor geneeskunde

2022 Volume 166

Abstract: Monkeypox (MPX) is a disease caused by the monkeypox virus. It is a viral zoonotic disease, endemic in Central and West Africa. Human-to-human spread also occurs and is a feature of the current global outbreak. As far as we know, exponential transmission ...

Title translation	Monkeypox, a new pandemic?
Abstract	Monkeypox (MPX) is a disease caused by the monkeypox virus. It is a viral zoonotic disease, endemic in Central and West Africa. Human-to-human spread also occurs and is a feature of the current global outbreak. As far as we know, exponential transmission during this outbreak is not related to changed viral characteristics but due to multiple high-risk contacts in a subset of people that have contracted the virus, so far almost exclusively affecting men who have sex with men (MSM). Appropriate public health measures and increased alertness of all health care providers is needed to increase case-finding and decrease transmission. There is a real chance of MPX to become endemic in large parts of the world.
MeSH term(s)	Male ; Humans ; Mpox (monkeypox)/epidemiology ; Homosexuality, Male ; Pandemics ; Sexual and Gender Minorities ; Monkeypox virus
Language	Dutch
Publishing date	2022-09-08
Publishing country	Netherlands
Document type	English Abstract ; Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy.

Garcia Garrido, Hannah M / Schnyder, Jenny L / Haydari, Beheshta / Vollaard, Albert M / Tanck, Michael W T / de Bree, Godelieve J / Meek, Bob / Grobusch, Martin P / Goorhuis, Abraham

International journal of antimicrobial agents

2022 Volume 60, Issue 2, Page(s) 106629

Abstract	People living with HIV (PLWH) are at increased risk of pneumococcal infections compared with the general population. The objective of this study was to investigate the immunogenicity of the combined pneumococcal vaccination schedule in PLWH. In this prospective cohort study, adult PLWH on antiretroviral therapy and HIV-negative controls received the 13-valent pneumococcal conjugate vaccine (PCV13) at baseline followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at Month 2. Serotype-specific IgG levels of 24 vaccine serotypes were measured at Months 0, 2, 4, 6 and 12. The primary outcome was seroprotection at Month 4, defined as the proportion of patients with a post-immunisation IgG concentration of ≥1.3 μg/mL for ≥70% (17/24) of vaccine serotypes. Samples of 120 patients were analysed. Seroprotection at Month 4 was 49% (39/80) for PLWH and 82% (28/34) in controls. At Month 12, seroprotection had decreased to 23% (18/79) and 63% (22/35), respectively. Nadir CD4 count ≥200 cells/mm
MeSH term(s)	Adult ; Antibodies, Bacterial ; Antiretroviral Therapy, Highly Active ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans ; Immunogenicity, Vaccine ; Immunoglobulin G ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/immunology ; Prospective Studies ; Vaccines, Conjugate/immunology
Chemical Substances	13-valent pneumococcal vaccine ; 23-valent pneumococcal capsular polysaccharide vaccine ; Antibodies, Bacterial ; Immunoglobulin G ; Pneumococcal Vaccines ; Vaccines, Conjugate
Language	English
Publishing date	2022-06-24
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2022.106629
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾

Article ; Online: Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis.

Garrido, Hannah M Garcia / Schnyder, Jenny L / Tanck, Michael W T / Vollaard, Albert / Spijker, René / Grobusch, Martin P / Goorhuis, Abraham

EClinicalMedicine

2020 Volume 29-30, Page(s) 100576

Abstract: Background: The objective of this systematic review and meta-analysis was to summarise the literature regarding the immunogenicity of pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV) in adult people living with HIV ( ... ...

Abstract	Background: The objective of this systematic review and meta-analysis was to summarise the literature regarding the immunogenicity of pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV) in adult people living with HIV (PLWH) in the era of advanced combination antiretroviral therapy (cART). Methods: The systematic review protocol was published online (PROSPERO ID: CRD 42020153137). We searched Medline (Ovid), EMBASE (Ovid), and the Global Health Library for publications from 2000 to June 11, 2020. We included all studies in adult PLWH that reported vaccine immunogenicity outcomes. The primary outcome was seroconversion rate (SCR) after PCV, PPSV and PCV/PPSV combined. For random-effects meta-analysis, we included studies defining SCR as Findings: Our search identified 1597 unique studies, of which 115 were eligible for full-text assessment. Of these, 39 met the inclusion criteria (11 RCTs; 28 cohort studies). A high degree of heterogeneity was observed. Nineteen studies were included in the meta-analysis. Pooled overall SCRs were 42% (95% CI 30-56%), 44% (95% CI 33-55%) and 57% (95% CI 50-63%) for PLWH who received PPSV, PCV or a combination of PCV/PPSV, respectively. Compared to PPSV alone, a combination of PCV/PPSV yielded higher SCRs (OR 2.24 95% CI 1.41- 3.58), whereas we did not observe a significant difference in SCR between PCV and PPSV23 alone. There were no statistically significant differences in geometric mean post-vaccination antibody concentrations between vaccination schedules. Vaccination at higher CD4 cell counts improved immunogenicity in 8/21 studies, especially when PCV was administered. No studies assessed the long-term immunogenicity of PCV followed by PPSV23. Quality of evidence ranged from poor ( Interpretation: We show that the recommended immunisation schedule consisting of a combination of PCV13/PPSV23, is immunogenic in PLWH in the era of advanced cART. However, the durability of this vaccination schedule remains unknown and must be addressed in future research. Vaccination with PCV should be delayed until immunological recovery (CD4>200) in recently diagnosed PLWH for optimal immunogenicity. The evidence gathered here supports wide implementation of the combination of PCV/PPSV23 for all PLWH. We recommend reassessment of this strategy once higher-valent PCVs become available. Funding: HMGG is funded by a public research grant of ZonMw (project number 522004005).
Language	English
Publishing date	2020-11-23
Publishing country	England
Document type	Journal Article
ISSN	2589-5370
ISSN (online)	2589-5370
DOI	10.1016/j.eclinm.2020.100576
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Medicamenteuze behandeling van COVID-19.

de Boer, Mark G J / Gieling, Emilie M / van der Linden, Paul D / Sinha, Bhanu N M / Vollaard, Albert M

Nederlands tijdschrift voor geneeskunde

2020 Volume 164

Abstract: Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to ...

Title translation	The medicinal treatment of COVID-19: a brief update.
Abstract	Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.
MeSH term(s)	Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/pharmacology ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/pharmacology ; Alanine/therapeutic use ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/epidemiology ; Drug Repositioning/methods ; Drug Repositioning/standards ; Glucocorticoids/pharmacology ; Glucocorticoids/therapeutic use ; Humans ; Hydroxychloroquine/pharmacology ; Hydroxychloroquine/therapeutic use ; Netherlands/epidemiology ; Randomized Controlled Trials as Topic ; SARS-CoV-2/drug effects ; Treatment Outcome
Chemical Substances	Anti-Inflammatory Agents ; Antiviral Agents ; Glucocorticoids ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Hydroxychloroquine (4QWG6N8QKH) ; Alanine (OF5P57N2ZX)
Language	Dutch
Publishing date	2020-11-12
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Influenza vaccination in adult patients with solid tumours treated with chemotherapy.

Vollaard, Albert / Schreuder, Imke / Slok-Raijmakers, Lizzy / Opstelten, Wim / Rimmelzwaan, Guus / Gelderblom, Hans

European journal of cancer (Oxford, England : 1990)

2017 Volume 76, Page(s) 134–143

Abstract: Patients with solid tumours receiving chemotherapy are at risk for influenza complications. Yearly influenza vaccination is recommended to patients treated with chemotherapy. However, adherence to vaccination is low, most likely due to lack of data on ... ...

Abstract	Patients with solid tumours receiving chemotherapy are at risk for influenza complications. Yearly influenza vaccination is recommended to patients treated with chemotherapy. However, adherence to vaccination is low, most likely due to lack of data on efficacy, optimal timing and safety of vaccination. There is scarce evidence for the effectiveness of the influenza vaccine in adult patients with solid tumours and chemotherapy on reduction of pneumonia, decreased mortality and fewer interruptions of oncological treatment. A review of 20 non-randomised serological studies in adult patients with different cancer types and chemotherapy provides insight in general trends of response to vaccination. Overall, the magnitude of the antibody response after influenza vaccination (i.e. seroconversion) can be lower than in healthy controls, but the majority of patients with solid tumours is able to mount a timely, protective immunological response (i.e. seroprotection) regardless of chemotherapy schedule, similar to healthy controls. Small sample sizes, patient heterogeneity and lack of comparable study designs limit more specific recommendations related to cancer type and optimal timing of vaccination. The inactivated influenza vaccine is safe to administer to immunosuppressed patients; side-effects are similar to those in healthy individuals. Although vaccination before start of chemotherapy is preferred to ensure optimal protection in adults with solid tumours, also vaccination during chemotherapy can reduce influenza-related complications considering the overall trends in serological response. Given the increased morbidity and mortality of influenza, influenza vaccination should be advocated as an inexpensive and safe preventive measure in patients with solid tumours receiving chemotherapy.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Humans ; Immunocompromised Host/immunology ; Influenza Vaccines/therapeutic use ; Influenza, Human/immunology ; Influenza, Human/mortality ; Influenza, Human/prevention & control ; Neoplasms/drug therapy ; Pneumonia/mortality ; Pneumonia/prevention & control ; Practice Guidelines as Topic
Chemical Substances	Antineoplastic Agents ; Influenza Vaccines
Language	English
Publishing date	2017-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2017.02.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito